AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15929958
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (home oxygen therapy with an oxygen concentrator only)
Trial: 12912865
Drug: Topical capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical capsaicin (0.006%)
Trial: 1744422
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of molsidomine (n = 11)
Trial: 1744422
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of molsidomine (n = 8)
Trial: 31544382
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (sodium hyaluronate eye drops)
Trial: 25331981
Drug: Self-administered parent
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered parent training with minimal therapist contact (written material and brief weekly telephone consultations)
Trial: 25331981
Drug: Self-administered parent
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered parent training
Trial: 20969665
Drug: LGP‐HA+L (large-gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LGP‐HA+L (large-gel particle hyaluronic acid plus 0.3% lidocaine)
Trial: 20969665
Drug: LGP‐HA (large-gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LGP‐HA (large-gel particle hyaluronic acid without lidocaine)
Trial: 11955728
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 800 mg/day (20 milliliters po qAM)
Trial: 9536950
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg daily for one week)
Trial: 1695785
Drug: Alpha blockers
RxNorm normalized name: ALPHA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha blockers (e.g., prazosin, terazosin)
Trial: 1695785
Drug: Nonselective alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonselective alpha blockers (e.g., phenoxybenzamine)
Trial: 30654912
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation of 4000 IU daily for three years
Trial: 22105592
Drug: Metformin exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin exposure with contrast media (CM)
Trial: 16365066
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (50 mg/d)
Trial: 12801622
Drug: xuezhikang 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xuezhikang 1200 mg/day (600 mg twice daily)
Trial: 2865275
Drug: Ro 15‐1788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15‐1788 (2.5 mg)
Trial: 2865275
Drug: Midazolam (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.07 mg/kg IV bolus, maintained by 0.025 to 0.04 mg/kg/hr infusion for eight hours)
Trial: 27157027
Drug: Motivational text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational text message intervention adjunct to cognitive-behavioral therapy
Trial: 15925286
Drug: Impact (Japan)
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Impact (Japan) supplement (1 L/d for 5 days before surgery)
Trial: 15925286
Drug: Impact (Japan)
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Impact (Japan) supplement
Trial: 15521326
Drug: Novel controlled-release
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel controlled-release formulations of niacin based on polyethylene oxide (PEO) and hydroxypropylmethyl cellulose (HPMC) matrices.
Trial: 15521326
Drug: Formulation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation of interest (specific formulation not detailed).
Trial: 11526359
Drug: Photopheresis (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photopheresis (5 treatments)
Trial: 9232448
Drug: Birch allergen
RxNorm normalized name: sweet birch allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birch allergen immunotherapy (IT)
Trial: 8453021
Drug: Sublingual and
RxNorm normalized name: Buprenorphine and Naloxone Sublingual Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual and aerosolized nitroglycerin
Trial: 20537815
Drug: Employment (Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Employment (Drug or Money)
Trial: 20537815
Drug: Punishment (Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Punishment (Drug Only+Money Loss)
Trial: 20537815
Drug: Unemployment (Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unemployment (Drug Only)
Trial: 14606736
Drug: Musical motor
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Musical motor feedback (MMF) therapy, 15 sessions
Trial: 14606736
Drug: Conventional gait
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional gait therapy, 15 sessions
Trial: 11105402
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CAI and TCL
Trial: 8872686
Drug: Propofol 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.125 mg/kg injection, propofol 12.5 mcg/kg/min infusion
Trial: 8872686
Drug: Propofol 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.25 mg/kg injection, propofol 25 mcg/kg/min infusion
Trial: 8872686
Drug: Propofol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.5 mg/kg injection, propofol 50 mcg/kg/min infusion
Trial: 8872686
Drug: Fentanyl 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1.4 mcg/kg injection (positive control)
Trial: 1326277
Drug: High-dose marihuana
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose marihuana (2.53% delta 9-tetrahydrocannabinol)
Trial: 1326277
Drug: Low-dose marihuana
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose marihuana (1.26% delta 9-tetrahydrocannabinol)
Trial: 3880992
Drug: Digoxin (0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.50 mg intravenously in 20 minutes)
Trial: 22974804
Drug: losmapimod 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losmapimod 7.5 mg once daily (lower dose)
Trial: 22974804
Drug: losmapimod 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losmapimod 7.5 mg twice daily (higher dose)
Trial: 19890632
Drug: Recombinant poxviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant poxviral vaccine with GM-CSF
Trial: 19890632
Drug: Recombinant poxviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant poxviral vaccine without GM-CSF
Trial: 19890632
Drug: Recombinant poxviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant poxviral vaccine
Trial: 17917313
Drug: Continuous positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous positive airway pressure (CPAP) treatment for 3 months
Trial: 17917313
Drug: No CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No CPAP treatment (control)
Trial: 15388511
Drug: infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: infliximab 5 mg/kg every 6 weeks
Trial: 10442958
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose propofol (2-2.5 mg x kg(‐1) bolus then 200 microg x kg(‐1) x min(‐1))
Trial: 10442958
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose propofol (1-2.5 mg x kg(‐1) bolus then 100 microg x kg(‐1) x min(‐1))
Trial: 7771914
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride (0.1 mg/kg)
Trial: 21415050
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 200 mg plus methotrexate (MTX)
Trial: 21415050
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg plus methotrexate (MTX)
Trial: 19561422
Drug: MF59-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted vaccine (Sub/MF59)
Trial: 19561422
Drug: Nonadjuvanted split
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonadjuvanted split vaccine (split)
Trial: 17339550
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose levels (adjusted for age, sex, smoking, previous myocardial infarction, hypertension, waist‐to‐hip ratio, creatinine, DM, and use of aspirin, beta‐blockers, or statins)
Trial: 15230816
Drug: Budesonide 400
RxNorm normalized name: Budesonide 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400 microg twice daily for 1 month, 200 microg twice daily for 5 months
Trial: 15230816
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (DSCG) 10 mg three-times daily for 6 months
Trial: 1864315
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of mifepristone (RU 486)
Trial: 26038847
Drug: Rupatadine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 20 mg/day
Trial: 26038847
Drug: Rupatadine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 40 mg/day
Trial: 24887185
Drug: Linum usitatissimum
RxNorm normalized name: LINUM USITATISSIMUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linum usitatissimum L. (linseed) oil
Trial: 17324009
Drug: Plerixafor as
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor as a single mobilising agent
Trial: 17324009
Drug: Plerixafor in
RxNorm normalized name: plerixafor Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor in combination with G-CSF
Trial: 17324009
Drug: Plerixafor in
RxNorm normalized name: plerixafor Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor in combination with chemotherapy
Trial: 17324009
Drug: G-CSF therapy
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF therapy alone
Trial: 16182156
Drug: Codeine/acetaminophen 600/60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine/acetaminophen 600/60 mg
Trial: 11935151
Drug: ACE-inhibitors (specifically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-inhibitors (specifically enalapril, n = 8)
Trial: 11935151
Drug: ACE-inhibitors (enalapril,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-inhibitors (enalapril, n = 8)
Trial: 7587232
Drug: Unfractionated porcine
RxNorm normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated porcine heparin (20 U/kg for ex vivo evaluation)
Trial: 7587232
Drug: Unfractionated porcine
RxNorm normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated porcine heparin (varying doses for in vitro evaluation)
Trial: 2406328
Drug: Enprofylline 300
RxNorm normalized name: Enprofylline
DrugBank: Enprofylline (DB00824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline 300 mg b.i.d.
Trial: 7985256
Drug: Theophylline 300
RxNorm normalized name: theophylline 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 300 mg b.i.d.
Trial: 2406328
Drug: Enprofylline 450
RxNorm normalized name: Enprofylline
DrugBank: Enprofylline (DB00824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline 450 mg b.i.d.
Trial: 2406328
Drug: Theophylline 450
RxNorm normalized name: theophylline 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline 450 mg b.i.d.
Trial: 31621606
Drug: Occupational Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational Therapy (OT) for ten weeks
Trial: 30024661
Drug: ELF‐EMF therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELF‐EMF therapy
Trial: 22920798
Drug: Intradermal (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal (ID) delivery of insulin lispro
Trial: 22920798
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) delivery of insulin lispro
Trial: 9854758
Drug: titrated-dose oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: titrated-dose oxycodone and sustained-release morphine sulfate
Trial: 9854758
Drug: set-dose oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: set-dose oxycodone
Trial: 28099276
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (parotid injections only)
Trial: 26079801
Drug: Sufentanil Sublingual
RxNorm normalized name: SUFentanil Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil Sublingual Tablet System (SSTS) 15 μg
Trial: 23693018
Drug: neoadjuvant DE
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant DE combined with rh-endostatin (7.5 mg/m2, d1-d14, every 3 weeks)
Trial: 23693018
Drug: neoadjuvant DE
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant DE (docetaxel: 75 mg/m2, d1, epirubicin: 75 mg/m2, d1, every 3 weeks)
Trial: 15904632
Drug: Enoxaparin (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (0.75 mg/kg intravenous bolus)
Trial: 15904632
Drug: Heparin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (60 U/kg intravenous bolus)
Trial: 12610035
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin (1.57 mg or 45 IU on each of the 2 dosing days in part 1; 4.7 mg or 135 IU in part 2)
Trial: 10498559
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine (n = 55)
Trial: 2006659
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (triamterene and hydrochlorothiazide)
Trial: 2006659
Drug: Diuretics plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics plus methyldopa
Trial: 29794296
Drug: Gabapentin 1,300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 1,300 mg/day
Trial: 29794296
Drug: Gabapentin (1,300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1,300 mg/day and 900 mg/day)
Trial: 26561613
Drug: UNIMMAP (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UNIMMAP (multiple micronutrient preparation)
Trial: 20869928
Drug: 5% topical
RxNorm normalized name: BP 5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% topical tocotrienol
Trial: 15231900
Drug: IL-8 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-8 group (antibiotic therapy when IL-8 >70 pg/mL and/or CRP >10 mg/L)
Trial: 15231900
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group (antibiotic therapy according to the guidelines of each center)
Trial: 8133796
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (50 mg every 3 weeks for 18 months)
Trial: 3628442
Drug: 0.07 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 mg/kg diazepam
Trial: 3628442
Drug: 0.14 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.14 mg/kg diazepam
Trial: 3628442
Drug: 0.21 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.21 mg/kg diazepam
Trial: 29620994
Drug: 6 months
RxNorm normalized name: leuprolide 45 mg/6 months intramuscular kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 months of treatment
Trial: 21153933
Drug: Intrathecal 10
RxNorm normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 10 mg 5% levobupivacaine + 0.1 mg morphine (Group M)
Trial: 21153933
Drug: Intrathecal 10
RxNorm normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 10 mg 5% levobupivacaine + 20 mcg fentanyl (Group F)
Trial: 16002536
Drug: Oral ethinyl
RxNorm normalized name: ethinyl estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ethinyl oestradiol (EE) with cyproterone acetate (CA)
Trial: 16002536
Drug: Transdermal 17beta‐oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta‐oestradiol (E2) with cyproterone acetate (CA)
Trial: 16002536
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone esters
Trial: 10928760
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C treated group (0.2 mg/mL for five minutes)
Trial: 8822681
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 60mL saline and dextrose into the knee joint followed by submaximal exercise for 3 to 4 minutes
Trial: 8822681
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injection of fluid, followed by submaximal exercise for 3 to 4 minutes
Trial: 1424419
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg lansoprazole administered once daily for 10 days
Trial: 1424419
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once daily for 10 days
Trial: 21426372
Drug: SB-656933 400
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-656933 400 mg
Trial: 21426372
Drug: SB-656933 50
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-656933 50 mg
Trial: 21426372
Drug: SB-656933 150
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-656933 150 mg
Trial: 19628647
Drug: Prednisone plus
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone plus ramipril (combination therapy group)
Trial: 19628647
Drug: Ramipril alone
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril alone (monotherapy group)
Trial: 16765398
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sulfadoxine/pyrimethamine (single dose) and artesunate (3 daily doses of 4 mg/kg)
Trial: 16765398
Drug: Amodiaquine and
RxNorm normalized name: Amodiaquine and artesunate only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine and artesunate (3 daily doses)
Trial: 9754844
Drug: Fluvoxamine (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (160 mg average daily dosage, highest permitted dose of 300 mg/day)
Trial: 7820711
Drug: Surfactant treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant treatment (Curosurf), dosage and duration not specified
Trial: 7820711
Drug: Immediate response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immediate response to surfactant treatment
Trial: 21594708
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MMC) treatment
Trial: 21900715
Drug: Induction arm
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction arm (IA): pegylated interferon-α2a 270 μg/week plus ribavirin 1,600 mg daily for 4 weeks, followed by pegylated interferon-α2a at standard dosages plus weight-based ribavirin for 8 weeks.
Trial: 21900715
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy arm (SA): pegylated interferon-α2a plus weight-based ribavirin for 12 weeks.
Trial: 21900715
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy arm (SA)
Trial: 16273807
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments from Swedish RA registry and biologics registries (ARTIS, SSATG, STURE)
Trial: 9814461
Drug: Dexamethasone treatment
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone treatment during pregnancy